The lack of p53 increase upon HEATR1 inhibition is not due to GBM cells being unable to activate RPL5/RPL11-MDM2-p53 signalling as low ActD dosage, which leads to the pathway activation (Holmberg Olausson et al, 2012), results in robust p53 accumulation (Appendix Fig. S6C). Here, RPL5 is linked to glioblastoma.